Distribution Fact Sheet

ASPARLAS®
(calaspargase pegol-mknl)
750 units/mL injection

oncaspar®
pegaspargase
750 units/mL injection

ASPARLAS INDICATIONS AND USAGE

ASPARLAS® (calaspargase pegol-mknl) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years.

ONCASPAR INDICATIONS AND USAGE

ONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with:

- First-line acute lymphoblastic leukemia (ALL)
- ALL and hypersensitivity to native forms of L-asparaginase

SPECIALTY DISTRIBUTOR

Order **ASPARLAS** and **ONCASPAR** through Cardinal Health™

For those who are new to working with Cardinal Health Specialty Pharmaceutical Distribution (SPD), please call 1-866-677-4844 and ask for help setting up an account.

Ordering Information:

Online

These products are available to order via OrderExpress:
www.orderexpress.cardinalhealth.com or www.specialtyonline.cardinalhealth.com

Email

Contact
GMB-SPD-MFGSERVICESSP@cardinalhealth.com

Phone

Call
1-855-740-1867 to place an order by phone

	Description	Strength/Size[1,2]	Supplier	J-Code[3]	NDC Number[1,2]*	Cardinal Health Number (CIN)
	ASPARLAS (calaspargase pegol-mknl)	3750 U/5 mL single-dose vial	Servier Pharmaceuticals	J9118	72694-515-01 72694-0515-01	5568696
	ONCASPAR (pegaspargase)	3750 IU/5 mL single-dose vial	Servier Pharmaceuticals	J9266	72694-954-01 72694-0954-01	5606769

All ONCASPAR orders are being processed through the ServierONE™ Eligibility Ordering Portal available at **https://www.servierone.com/hcp/financial-support/oncaspar/** or **oncasparportal.com**

See page 2 for additional details.

*The red zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.

NDC, National Drug Code.

Please see page 3 for Important Safety Information and click here for Full Prescribing Information for ASPARLAS, and click here for Full Prescribing Information for ONCASPAR.

SERVIER

ONCASPAR Ordering Information

Ordering Process for ONCASPAR

oncaspar® pegaspargase 750 units/mL injection

SERVIER ONE™

- All ONCASPAR orders are being processed through the ServierONE Eligibility Ordering Portal available at **https://www.servierone.com/hcp/financial-support/oncaspar/** or **oncasparportal.com**
- If a patient is eligible to receive ONCASPAR, an Ordering Code will be generated through the Portal and the ONCASPAR order can be placed directly with Cardinal Health at **GMB-SPD-MFGSERVICESSP@cardinalhealth.com** or via phone at 1-855-740-1867
- For additional information on the ONCASPAR Ordering Process, please visit **https://www.servierone.com/hcp/financial-support/oncaspar/**, call the ServierONE Patient Support Services team to speak to a dedicated Patient Experience Manager at 1-800-813-5905, or email the team at **uspatientservices@servier.com**

SPECIALTY PHARMACY

ASPARLAS and **ONCASPAR** are available through Biologics by McKesson

Online
biologics.mckesson.com

Email
mycareteam@biologicsinc.com

Phone
Call
1-800-850-4306

Fax
1-800-823-4506

> Please visit www.asparlas.com/SRV_HCP_Asparlas for more information about ASPARLAS

> Please visit https://www.oncaspar.com/hcp/ for more information about ONCASPAR

Servier does not make any warranty as to the services offered by any particular authorized distributor.

Please see page 3 for Important Safety Information and click here for Full Prescribing Information for ASPARLAS, and click here for Full Prescribing Information for ONCASPAR.

SERVIER

IMPORTANT SAFETY INFORMATION FOR ASPARLAS AND ONCASPAR

Contraindications for ASPARLAS and ONCASPAR

- History of serious hypersensitivity reactions to ASPARLAS (calaspargase pegol-mknl) or ONCASPAR (pegaspargase) or to any of the excipients.
- History of serious thrombosis with prior L-asparaginase therapy.
- History of serious pancreatitis, including pancreatitis related to prior L-asparaginase therapy.
- History of serious hemorrhagic events with prior L-asparaginase therapy.
- Severe hepatic impairment.

Warnings and Precautions for ASPARLAS and ONCASPAR

Anaphylaxis and Serious Hypersensitivity Reactions: Anaphylaxis and serious hypersensitivity reactions can occur with ASPARLAS or ONCASPAR. Grade 3 and 4 hypersensitivity reactions including anaphylaxis have been reported in clinical trials with ASPARLAS and ONCASPAR. The risk of serious hypersensitivity reactions is higher in patients with known hypersensitivity to *(E.) coli* derived L-asparaginase formulations. Premedicate patients 30-60 minutes prior to administration of ASPARLAS or ONCASPAR. Observe patients for 1 hour after administration in a clinical setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Discontinue ASPARLAS or ONCASPAR in patients with serious hypersensitivity reactions.

Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis, were seen in clinical trials with ASPARLAS and ONCASPAR. Discontinue ASPARLAS or ONCASPAR in patients with serious thrombotic events.

Pancreatitis: Pancreatitis can occur and has been reported in clinical trials with ASPARLAS and ONCASPAR. Fatal outcomes have been reported. Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Assess serum amylase and/or lipase levels to identify early signs of pancreatic inflammation. Discontinue ASPARLAS or ONCASPAR in patients where pancreatitis is suspected. If pancreatitis is confirmed, do not resume ASPARLAS or ONCASPAR.

Glucose Intolerance: Glucose intolerance can occur and was seen in patients receiving ONCASPAR. In some cases, it can be irreversible. Monitor serum glucose in patients receiving ASPARLAS or ONCASPAR.

Hemorrhage: Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia can occur. Evaluate patients with signs and symptoms of hemorrhage with coagulation parameters including PT, PTT, and fibrinogen. Consider appropriate replacement therapy in patients with severe or symptomatic coagulopathy. Discontinue ASPARLAS or ONCASPAR for severe or life-threatening hemorrhage.

Hepatotoxicity: Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of hepatic veno-occlusive disease (VOD), have been observed in patients treated with ASPARLAS or ONCASPAR in combination with standard chemotherapy, including during the induction phase of multiphase chemotherapy. Do not administer ASPARLAS or ONCASPAR to patients with severe hepatic impairment. Evaluate bilirubin and transaminases prior to each dose of ASPARLAS or ONCASPAR and at least weekly, during cycles of treatment that include ASPARLAS or ONCASPAR, through 6 weeks after the last dose of ASPARLAS or ONCASPAR. Monitor frequently for signs and symptoms of hepatic VOD, which may include rapid weight gain, fluid retention with ascites, hepatomegaly (which may be painful), and rapid increase of bilirubin. For patients who develop abnormal liver tests after ASPARLAS or ONCASPAR, more frequent monitoring for liver test abnormalities and clinical signs and symptoms of VOD is recommended. In the event of serious liver toxicity, including VOD, discontinue treatment with ASPARLAS or ONCASPAR and provide supportive care.

Adverse Reactions for ASPARLAS

The most common grade 3 and above adverse reactions (incidence ≥10%) for patients receiving ASPARLAS with multiagent chemotherapy observed in the DFCI clinical trial were elevated transaminases (52%), increased bilirubin (20%), pancreatitis (18%) and abnormal clotting studies (14%). There was 1 fatal adverse reaction (multi-organ failure in the setting of chronic pancreatitis associated with a pancreatic pseudocyst). Not all grade 1 and 2 adverse reactions were collected prospectively.

Adverse Reactions for ONCASPAR

The most common grade 3 and 4 adverse reactions with ONCASPAR (>5%) included hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections.

Please see the Full Prescribing Information for ASPARLAS and Full Prescribing Information for ONCASPAR.

References: 1. ASPARLAS [package insert]. Boston, MA: Servier Pharmaceuticals LLC; 2023. **2.** ONCASPAR [package insert]. Boston, MA: Servier Pharmaceuticals LLC; 2024. **3.** Centers for Medicare and Medicaid Services. HCPCS quarterly update. March 26, 2025. Accessed April 9, 2025. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update

© 2025 Servier Pharmaceuticals LLC. Boston, MA 02210. Customer Service: 1-800-807-6124. Servier and the Servier Logo are registered trademarks of LES LABORATOIRES SERVIER. ASPARLAS and ONCASPAR are registered trademarks of SERVIER PHARMACEUTICALS LLC, a wholly owned, indirect subsidiary of LES LABORATOIRES SERVIER. Cardinal Health is a trademark of Cardinal Health Technologies, LLC.
US-02482 04/2025

SERVIER